The Study of Heart and Renal Protection (SHARP) was a study in finding out the benefit of taking statins (a type of drug that lowers cholesterol) in patients with kidney disease. We coordinated sites in Canada and recruited 505 volunteers aged 40 or over with chronic kidney disease towards the global total of 9,500 volunteers in 18 countries. The study found that around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. Because of this strong scientific evidence, statins are now recommended as part of the standard medication regime for patients with kidney disease in BC.